Showing 672 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

Editor's pick
ViiV Healthcare press release
21 January 2014
The search for a cure

NIH-created toxin can kill HIV-infected cells that persist despite treatment

Editor's pick
Eurekalert Medicine & Health
10 January 2014
HIV treatment for children & young people

Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension

Editor's pick
Wall Street Journal
9 January 2014
New & experimental HIV treatments

Vertex's VX-765 holds promise for HIV treatment

Editor's pick
Motley Fool
7 January 2014
New & experimental HIV treatments

New anti-HIV drug target identified

Editor's pick
Medical Xpress
19 December 2013
New & experimental HIV treatments

Lupin launches HIV drug in the US

Editor's pick
The Hindu
19 December 2013
Changing treatment

U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

Editor's pick
Gilead press release
16 December 2013
The search for a cure

Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load

Editor's pick
Sangamo Biosciences press release
10 December 2013
New & experimental HIV treatments

Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

Editor's pick
European Medicines Agency
26 November 2013
New & experimental HIV treatments

Gilead's Vitekta Gets Approval in European Union

Editor's pick
Wall Street Journal
19 November 2013
Treatment guidelines

Recommendation on Integrase Inhibitor Use in Antiretroviral Treatment-Naive HIV-Infected Individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents

Editor's pick
AIDS Info
31 October 2013
New & experimental HIV treatments

Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia

Editor's pick
Sangamo press release
29 October 2013
New & experimental HIV treatments

ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine

Editor's pick
Viiv Healthcare
23 October 2013
New & experimental HIV treatments

HIV Dual Therapy Matches Standard Triple Cocktail

Editor's pick
MedPage Today
19 October 2013
New & experimental HIV treatments

MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again

Editor's pick
NEJM Journal Watch
17 October 2013
The search for a cure

Elusive secret of HIV long-term immunity

Editor's pick
EurekAlert!
17 October 2013
Drug interactions & pharmacokinetics

Merck plans phase III study of once-daily raltegravir (Isentress)

Editor's pick
Merck press release
16 October 2013
New & experimental HIV treatments

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Editor's pick
News Medical Net
15 October 2013
New & experimental HIV treatments

Viriom Reports Clinical Efficacy Data for VM-1500, a New HIV NNRTI

Editor's pick
Marketwired (press release)
8 October 2013
The search for a cure

Gladstone lab uncovers a potential HIV cure — and it's already a drug

Editor's pick
San Francisco Business Times
6 October 2013
PrEP

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

Editor's pick
The Body Pro
6 October 2013
New & experimental HIV treatments

From sky high to CHAI – what needs to be done about dolutegravir pricing?

Editor's pick
HIV I-Base
2 October 2013
New & experimental HIV treatments

European Commission Approves Gilead Sciences' Tybost(TM), a New Boosting Agent for HIV Therapy

Editor's pick
Gilead press release
26 September 2013
PrEP

PATH Evaluates Janssen’s Rilpivirine as HIV Infection Prophylactic

Editor's pick
Genetic Engineering & Biotechnology News
25 September 2013